With the help of $61 million from EW Healthcare Partners and a third-party investor, pSivida (NSDQ:PSDV) announced today that it acquired Icon Bioscience and its FDA-approved dexamethasone intraocular suspension designed to treat postoperative inflammation. The two companies combined and plan to do business as EyePoint Pharmaceuticals.
pSivida also landed a $20 million debt facility from SWK Holdings Corp., to help fund the Icon buyout and prepare for the commercial launch of Icon’s Dexycu product.
Get the full story at our sister site, Drug Delivery Business News.
The post pSivida buys Icon Bioscience and rebrands as EyePoint Pharmaceuticals appeared first on MassDevice.
from MassDevice https://ift.tt/2us3809
Cap comentari:
Publica un comentari a l'entrada